AHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
American Healthcare REIT Inc (AHR) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the stock has positive analyst sentiment and long-term growth potential, the recent financial performance, insider selling, and technical indicators suggest caution. The stock is oversold, but the lack of strong upward momentum and declining financial metrics make it a hold rather than a buy.
The stock is currently oversold with an RSI of 15.413, indicating potential for a rebound. However, the MACD is negatively expanding (-0.692), and moving averages are converging, showing no clear bullish trend. The stock is trading below the pivot level of 50.299, with key support at 47.877 and resistance at 52.721.
Analysts have raised price targets recently, with targets ranging from $55 to $60, and maintain positive ratings. The company declared a consistent quarterly dividend of $0.25 per share, which may appeal to income-focused investors.
Insiders are selling heavily, with a 148.13% increase in selling activity over the last month. The company's financial performance in Q4 2025 showed a significant decline in net income (-133.91% YoY) and EPS (-128.57% YoY). Gross margin also dropped by 4.28%.
In Q4 2025, revenue increased by 11.30% YoY to $604.08M, but net income dropped significantly to $10.78M (-133.91% YoY). EPS fell to 0.06 (-128.57% YoY), and gross margin declined to 18.55% (-4.28% YoY).
Analysts are bullish on the stock, with multiple firms raising price targets recently. Truist raised the target to $57, Scotiabank to $59, UBS to $60, and Citi to $55. Ratings include Buy and Outperform, with positive sentiment on growth prospects and fundamentals.
